HK1115011A1 - Potassium salt of an hiv integrase inhibitor hiv - Google Patents
Potassium salt of an hiv integrase inhibitor hivInfo
- Publication number
- HK1115011A1 HK1115011A1 HK08104747.0A HK08104747A HK1115011A1 HK 1115011 A1 HK1115011 A1 HK 1115011A1 HK 08104747 A HK08104747 A HK 08104747A HK 1115011 A1 HK1115011 A1 HK 1115011A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hiv
- potassium salt
- integrase inhibitor
- hiv integrase
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63313204P | 2004-12-03 | 2004-12-03 | |
| PCT/US2005/043781 WO2006060730A2 (en) | 2004-12-03 | 2005-12-02 | Potassium salt of an hiv integrase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1115011A1 true HK1115011A1 (en) | 2008-11-14 |
Family
ID=36171569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK08104747.0A HK1115011A1 (en) | 2004-12-03 | 2008-04-29 | Potassium salt of an hiv integrase inhibitor hiv |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US7754731B2 (sr) |
| EP (2) | EP1819683B1 (sr) |
| JP (1) | JP4705956B2 (sr) |
| KR (2) | KR101350420B1 (sr) |
| CN (1) | CN101068793B (sr) |
| AR (2) | AR052034A1 (sr) |
| AT (2) | ATE534645T1 (sr) |
| AU (1) | AU2005311671B8 (sr) |
| BR (1) | BRPI0518760A8 (sr) |
| CA (1) | CA2588398C (sr) |
| CR (1) | CR9146A (sr) |
| CY (1) | CY1112859T1 (sr) |
| DK (1) | DK1819700T3 (sr) |
| EA (1) | EA012418B1 (sr) |
| ES (2) | ES2370136T3 (sr) |
| GE (1) | GEP20105086B (sr) |
| HK (1) | HK1115011A1 (sr) |
| HR (1) | HRP20120066T1 (sr) |
| IL (1) | IL183614A (sr) |
| MA (1) | MA29120B1 (sr) |
| ME (1) | ME01985B (sr) |
| MX (1) | MX2007006639A (sr) |
| MY (1) | MY144320A (sr) |
| NI (1) | NI200700138A (sr) |
| NO (1) | NO338784B1 (sr) |
| NZ (1) | NZ555376A (sr) |
| PE (1) | PE20061148A1 (sr) |
| PL (1) | PL1819700T3 (sr) |
| PT (1) | PT1819700E (sr) |
| RS (1) | RS52197B (sr) |
| SI (1) | SI1819700T1 (sr) |
| TN (1) | TNSN07215A1 (sr) |
| TW (1) | TWI344463B (sr) |
| UA (1) | UA87884C2 (sr) |
| WO (2) | WO2006060712A2 (sr) |
| ZA (1) | ZA200704130B (sr) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842820B2 (en) | 2004-03-11 | 2010-11-30 | 4Sc Ag | Sulfonylpyrroles |
| JP2008521934A (ja) * | 2004-12-03 | 2008-06-26 | メルク エンド カムパニー インコーポレーテッド | Ｕｇｔ１ａ１によって代謝される薬物の薬物動態を改善するためのアタザナビルの使用 |
| CA2588465C (en) * | 2004-12-03 | 2013-10-01 | Merck & Co., Inc. | Pharmaceutical composition containing an anti-nucleating agent |
| WO2006060711A2 (en) * | 2004-12-03 | 2006-06-08 | Merck & Co., Inc. | Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition |
| AU2007226626B8 (en) * | 2006-03-14 | 2012-10-18 | Merck Sharpe & Dohme Corp. | Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use |
| MX2009000661A (es) | 2006-07-19 | 2009-03-27 | Univ Georgia Res Found | Piridinon-diceto-acidos: inhibidores de replicacion de vih en terapia de combinacion. |
| WO2009009531A2 (en) * | 2007-07-09 | 2009-01-15 | Concert Pharmaceuticals Inc. | Pyrimidinecarboxamide derivatives for the treatment of hiv infections |
| WO2009088729A1 (en) * | 2008-01-08 | 2009-07-16 | Merck & Co., Inc. | Process for preparing n-substituted hydroxypyrimidinone carboxamides |
| US8742105B2 (en) | 2009-06-02 | 2014-06-03 | Hetero Research Foundation | Polymorphs of raltegravir potassium |
| WO2011024192A2 (en) | 2009-07-27 | 2011-03-03 | Matrix Laboratories Ltd | Novel polymorphs of raltegravir |
| AU2010313571B2 (en) * | 2009-10-26 | 2014-07-31 | Merck Sharp & Dohme Llc | Solid pharmaceutical compositions containing an integrase inhibitor |
| DE102009056636A1 (de) | 2009-12-02 | 2011-06-09 | Ratiopharm Gmbh | Raltegravir-Polymorphe |
| KR20120094098A (ko) * | 2009-12-07 | 2012-08-23 | 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 | 피리디논 하이드록시사이클로펜틸 카복사미드: 치료 용도의 ｈｉｖ 인테그라제 억제제 |
| ES2362598B1 (es) * | 2009-12-17 | 2012-06-13 | Consejo Superior De Investigaciones Científicas (Csic) | Uso del raltegravir y derivados para la elaboración de medicamentos destinados al tratamiento de infecciones por herpesvirus. |
| WO2011123754A1 (en) | 2010-04-01 | 2011-10-06 | Teva Pharmaceutical Industries Ltd. | Raltegravir salts and crystalline forms thereof |
| EP2552915B1 (en) * | 2010-04-01 | 2017-07-19 | Critical Outcome Technologies Inc. | Compounds for the treatment of hiv |
| WO2011148381A1 (en) * | 2010-05-25 | 2011-12-01 | Hetero Research Foundation | Salts of raltegravir |
| WO2012009446A1 (en) | 2010-07-16 | 2012-01-19 | Concert Pharmaceuticals Inc. | Novel pyrimidinecarboxamide derivatives |
| CN101914067B (zh) * | 2010-08-26 | 2012-07-11 | 陈岱岭 | N-甲基嘧啶酮的合成方法 |
| JO3209B1 (ar) * | 2010-11-05 | 2018-03-08 | H Lundbeck As | طريقة لتصنيع نالتريكسون |
| WO2012103105A1 (en) | 2011-01-24 | 2012-08-02 | Assia Chemical Industries Ltd. | Processes for preparing raltegravir and intermediates in the processes |
| WO2012106534A2 (en) * | 2011-02-02 | 2012-08-09 | The Regents Of The University Of California | Hiv integrase inhibitors |
| WO2012137142A1 (en) | 2011-04-06 | 2012-10-11 | Lupin Limited | Novel salts of raltegravir |
| JP2014512386A (ja) * | 2011-04-22 | 2014-05-22 | メルク・シャープ・アンド・ドーム・コーポレーション | 味がマスクされたラルテグラビル製剤 |
| US9968607B2 (en) | 2011-04-25 | 2018-05-15 | Hetero Research Foundation | Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof |
| EP2522665A1 (en) | 2011-05-03 | 2012-11-14 | Sandoz Ag | Crystalline sodium salt of an HIV integrase inhibitor |
| ES2450944T3 (es) | 2011-06-01 | 2014-03-25 | Ratiopharm Gmbh | Composición y comprimido que comprenden raltegravir |
| WO2013037731A1 (de) | 2011-09-16 | 2013-03-21 | Hexal Ag | Neue polymorphe form von raltegravir-kalium |
| CN103130788B (zh) * | 2011-11-24 | 2015-09-02 | 南开大学 | 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性 |
| CN103130787B (zh) * | 2011-11-24 | 2015-06-10 | 南开大学 | 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性 |
| EP2804607B1 (en) | 2011-12-26 | 2020-09-16 | Emcure Pharmaceuticals Limited | Synthesis of raltegravir |
| BR112014018247A8 (pt) | 2012-01-25 | 2017-07-11 | Lupin Ltd | Pré-mistura de potássio de raltegravir amorfa e estável; processo; formulação farmacêutica; e método |
| WO2014064711A2 (en) * | 2012-10-22 | 2014-05-01 | Hetero Research Foundation | Methods of administering raltegravir and raltegravir compositions |
| EP2818470A1 (en) | 2013-06-27 | 2014-12-31 | Basf Se | Cocrystals of raltegravir potassium |
| EP3022209B1 (en) | 2013-07-17 | 2018-03-07 | ratiopharm GmbH | Dolutegravir potassium salt |
| CA2938387C (en) | 2014-02-03 | 2021-03-02 | Mylan Laboratories Ltd | Processes for the preparation of intermediates of raltegravir |
| WO2015140765A1 (en) | 2014-03-21 | 2015-09-24 | Mylan Laboratories Ltd. | A premix of crystalline raltegravir potassium salt and a process for the preparation thereof |
| US10257840B2 (en) | 2014-10-22 | 2019-04-09 | Telefonaktiebolaget Lm Ericsson (Publ) | Operation of wireless local area network in the presence of periodic interference |
| US10259778B2 (en) | 2014-11-10 | 2019-04-16 | Aurobindo Pharma Ltd | Process for the preparation of raltegravir |
| WO2017220208A1 (en) * | 2016-06-21 | 2017-12-28 | Pharmathen S.A. | Process for preparing compounds useful as intermediates for the preparation of raltegravir |
| AU2017329049A1 (en) | 2016-09-15 | 2019-04-04 | Lupin Limited | Process for the preparation of pure and stable crystalline Raltegravir potassium Form 3 |
| CN108610338A (zh) * | 2016-12-12 | 2018-10-02 | 天津国际生物医药联合研究院 | 一种嘧啶酮酰胺类化合物的制备方法 |
| HRP20220613T1 (hr) | 2017-11-14 | 2022-06-24 | Cambrex Profarmaco Milano S.R.L. | Postupak priprave raltegavira |
| US20210290548A1 (en) * | 2018-06-06 | 2021-09-23 | Merck Sharp & Dohme Corp. | Formulations of raltegravir |
| GB201907305D0 (en) * | 2019-05-23 | 2019-07-10 | Douglas Pharmaceuticals Ltd | Treatment of conditions |
| WO2021148992A1 (en) | 2020-01-23 | 2021-07-29 | Lupin Limited | Pharmaceutical compositions of raltegravir |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH624391A5 (sr) * | 1976-12-14 | 1981-07-31 | Ciba Geigy Ag | |
| US5717097A (en) | 1991-11-08 | 1998-02-10 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| IL121789A (en) * | 1996-10-03 | 2001-06-14 | Rohm & Haas | A medicinal product for inhibiting mammalian cell tumors |
| CZ20012160A3 (cs) | 1998-12-25 | 2001-10-17 | Shionogi & Co., Ltd. | Heteroaromatické deriváty s inhibiční aktivitou proti HIV integráze |
| IT1318424B1 (it) | 2000-03-24 | 2003-08-25 | Unihart Corp | Composti con attivita' anti-hiv. |
| EE200300145A (et) | 2000-10-12 | 2003-06-16 | Merck & Co., Inc. | Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon |
| GB0028483D0 (en) | 2000-11-22 | 2001-01-10 | Hoffmann La Roche | Hydroxyethylamine HIV protease inhibitors |
| PT1441735E (pt) | 2001-10-26 | 2006-06-30 | Istituto Di Ricerche Di B Mo P | Inibidores de integrase do hiv a base de hidroxipirimidinona carboxamida n-substituida |
| CA2467718C (en) | 2001-12-21 | 2011-04-26 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| WO2004046115A1 (ja) | 2002-11-20 | 2004-06-03 | Japan Tobacco Inc. | ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用 |
| BR0317749A (pt) | 2002-12-27 | 2005-11-22 | Angeletti P Ist Richerche Bio | Composto, composição farmacêutica, e, uso de um composto |
| TW200423930A (en) | 2003-02-18 | 2004-11-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitors |
| WO2006060711A2 (en) * | 2004-12-03 | 2006-06-08 | Merck & Co., Inc. | Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition |
| CA2588465C (en) | 2004-12-03 | 2013-10-01 | Merck & Co., Inc. | Pharmaceutical composition containing an anti-nucleating agent |
| JP2008521934A (ja) | 2004-12-03 | 2008-06-26 | メルク エンド カムパニー インコーポレーテッド | Ｕｇｔ１ａ１によって代謝される薬物の薬物動態を改善するためのアタザナビルの使用 |
-
2005
- 2005-02-12 UA UAA200707372A patent/UA87884C2/uk unknown
- 2005-11-24 AR ARP050104911A patent/AR052034A1/es not_active Application Discontinuation
- 2005-11-25 TW TW094141625A patent/TWI344463B/zh active
- 2005-11-25 MY MYPI20055516A patent/MY144320A/en unknown
- 2005-12-01 PE PE2005001398A patent/PE20061148A1/es not_active Application Discontinuation
- 2005-12-02 PL PL05852840T patent/PL1819700T3/pl unknown
- 2005-12-02 AU AU2005311671A patent/AU2005311671B8/en active Active
- 2005-12-02 EP EP05852866A patent/EP1819683B1/en active Active
- 2005-12-02 MX MX2007006639A patent/MX2007006639A/es active IP Right Grant
- 2005-12-02 GE GEAP200510157A patent/GEP20105086B/en unknown
- 2005-12-02 BR BRPI0518760A patent/BRPI0518760A8/pt not_active Application Discontinuation
- 2005-12-02 EA EA200701204A patent/EA012418B1/ru not_active IP Right Cessation
- 2005-12-02 US US11/293,678 patent/US7754731B2/en active Active
- 2005-12-02 KR KR1020077015278A patent/KR101350420B1/ko active IP Right Grant
- 2005-12-02 WO PCT/US2005/043728 patent/WO2006060712A2/en active Application Filing
- 2005-12-02 CN CN2005800416393A patent/CN101068793B/zh active Active
- 2005-12-02 NZ NZ555376A patent/NZ555376A/en unknown
- 2005-12-02 ME MEP-2012-21A patent/ME01985B/me unknown
- 2005-12-02 EP EP05852840A patent/EP1819700B1/en active Active
- 2005-12-02 DK DK05852840.7T patent/DK1819700T3/da active
- 2005-12-02 WO PCT/US2005/043781 patent/WO2006060730A2/en active Application Filing
- 2005-12-02 AT AT05852840T patent/ATE534645T1/de active
- 2005-12-02 CA CA2588398A patent/CA2588398C/en active Active
- 2005-12-02 JP JP2007544570A patent/JP4705956B2/ja active Active
- 2005-12-02 RS RS20120021A patent/RS52197B/sr unknown
- 2005-12-02 AT AT05852866T patent/ATE518844T1/de active
- 2005-12-02 KR KR1020137028450A patent/KR20130122031A/ko not_active Application Discontinuation
- 2005-12-02 ES ES05852866T patent/ES2370136T3/es active Active
- 2005-12-02 PT PT05852840T patent/PT1819700E/pt unknown
- 2005-12-02 SI SI200531435T patent/SI1819700T1/sl unknown
- 2005-12-02 ES ES05852840T patent/ES2375788T3/es active Active
-
2007
- 2007-05-22 ZA ZA200704130A patent/ZA200704130B/xx unknown
- 2007-05-23 CR CR9146A patent/CR9146A/es not_active Application Discontinuation
- 2007-05-28 NI NI200700138A patent/NI200700138A/es unknown
- 2007-05-31 IL IL183614A patent/IL183614A/en active IP Right Grant
- 2007-06-01 TN TNP2007000215A patent/TNSN07215A1/fr unknown
- 2007-06-29 MA MA30041A patent/MA29120B1/fr unknown
- 2007-07-02 NO NO20073404A patent/NO338784B1/no unknown
-
2008
- 2008-04-29 HK HK08104747.0A patent/HK1115011A1/xx unknown
-
2010
- 2010-06-04 US US12/793,801 patent/US8357798B2/en active Active
-
2012
- 2012-01-23 HR HR20120066T patent/HRP20120066T1/hr unknown
- 2012-02-21 CY CY20121100173T patent/CY1112859T1/el unknown
-
2014
- 2014-04-24 AR ARP140101707A patent/AR101429A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1115011A1 (en) | Potassium salt of an hiv integrase inhibitor hiv | |
| EP1725535A4 (en) | HIV integrase | |
| EP1756069A4 (en) | HIV INTEGRASE INHIBITORS | |
| IL177189A0 (en) | Hiv integrase inhibitors | |
| IL177858A0 (en) | Hiv integrase inhibitors | |
| EP1725102A4 (en) | HIV integrase | |
| SI1948666T1 (sl) | Hiv integrazni inhibitorji | |
| TWI366567B (en) | Bicyclic heterocycles as hiv integrase inhibitors | |
| EP1756114A4 (en) | HIV integrase | |
| EP1881825A4 (en) | INHIBITORS OF HIV INTEGRASE | |
| EP1753767A4 (en) | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | |
| EP1749008A4 (en) | BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS | |
| IL179161A0 (en) | Hiv integrase inhibitors: cyclic pyrimidinone compounds | |
| AU2003248872A8 (en) | Hiv integrase inhibitors | |
| EP1758585A4 (en) | HIV integrase | |
| EP1910363A4 (en) | INHIBITORS OF HIV INTEGRASE | |
| TWI365876B (en) | Prodrugs of hiv protease inhibitors | |
| EP1910356A4 (en) | HIV integrase | |
| AP2008004400A0 (en) | Inhibitors of HIV integrase enzyme | |
| EP1910355A4 (en) | HIV integrase | |
| EP1909578A4 (en) | INHIBITORS OF HIV INTEGRASE | |
| ZA200609935B (en) | Bicyclic heterocycles as HIV integrase inhibitors | |
| ZA200606956B (en) | HIV integrase inhibitors | |
| ZA200702390B (en) | S-triazolyl α-mercaptoacetanildes as inhibitors of HIV reverse transciptase | |
| GB0405586D0 (en) | Disposal of metal salts |